

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

VOLUNTARY ANNOUNCEMENT

APPROVAL BY THE NMPA FOR A PHASE II CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF LUPUS NEPHRITIS

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that the Group has received approval from the National Medical Products Administration of the People’s Republic of China (the “**NMPA**”) for a Phase II clinical trial of IMM0306, a first-in-class bispecific antibody targeting CD47xCD20, for the treatment of Lupus Nephritis (LN).

ABOUT IMM0306

IMM0306, independently developed by the Group, is a bispecific molecule targeting both cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20) and is the first CD47 and CD20 dual-targeting bispecific to enter into clinical stage globally. IMM0306 blocks the “don’t eat me” signal by inhibiting the CD47-SIRP α interaction, enhances Fc-Fc γ RIIIa and Fc-Fc γ RIIIa interactions to activate macrophages and NK cells, and preferentially binds CD20 over CD47 to effectively eliminate malignant B cells while minimizing toxicity, leading to improved therapeutic outcomes.

As of the date of this announcement, the Group owns the global intellectual property rights and commercial rights of IMM0306.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, IMM0306, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Shanghai, the PRC, December 2, 2024

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.